Chengdu Olymvax Biopharmaceuticals Inc. Class A

As of June 30, 2026, Chengdu Olymvax Biopharmaceuticals Inc. Class A carries a market capitalization of 17.83B, placing it among publicly traded companies globally. Its enterprise value stands at 18.12B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Chengdu Olymvax Biopharmaceuticals Inc. Class A's next confirmed earnings release is scheduled for October 30, 2026.

As of June 30, 2026, Chengdu Olymvax Biopharmaceuticals Inc. Class A has 405.41M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 22.95, and the price-to-book ratio stands at 20.51.

As of June 30, 2026, Chengdu Olymvax Biopharmaceuticals Inc. Class A trades at an EV/EBITDA multiple of 335.04 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 23.32 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 335.04 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 18.12B versus a market cap of 17.83B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Chengdu Olymvax Biopharmaceuticals Inc. Class A maintains a current ratio of 1.29, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 60.29, indicating elevated leverage, while an interest coverage ratio of 3.34 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Chengdu Olymvax Biopharmaceuticals Inc. Class A posted a negative return on equity (ROE) of -4.23, meaning shareholder capital produced losses rather than profits. Return on invested capital (ROIC) is negative at -6.01, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) is negative at -1.95, reflecting losses generated across the asset base. Return on capital employed (ROCE) is negative at -4.61, pointing to unprofitable operations over the period. The company generates approximately 1.70M in revenue per employee across its workforce of 455.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.81 indicates how many times Chengdu Olymvax Biopharmaceuticals Inc. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Chengdu Olymvax Biopharmaceuticals Inc. Class A recorded 60.46M in income tax expense. That works out to an effective tax rate of 251.36, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 24.05M, leaving -37.82M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Chengdu Olymvax Biopharmaceuticals Inc. Class A's stock has gained approximately 13.13% over the past 52 weeks. The 50-day moving average sits at 28.34, while the 200-day moving average is 30.12.

Over the twelve months ended June 30, 2026, Chengdu Olymvax Biopharmaceuticals Inc. Class A generated 776.92M in revenue and converted that into -37.82M in net income, yielding earnings per share of -0.09. EBITDA reached 54.08M, while operating income came in at 115.00M.

As of June 30, 2026, Chengdu Olymvax Biopharmaceuticals Inc. Class A holds 235.28M in cash and equivalents against 524.10M in total debt, resulting in a net debt position of 134.87M. Total book value stands at 869.33M, with working capital of 239.00M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Chengdu Olymvax Biopharmaceuticals Inc. Class A posted a gross margin of 92.37, reflecting its pricing power and cost economics. The operating margin of 14.80 and net profit margin of -4.87 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Chengdu Olymvax Biopharmaceuticals Inc. Class A paid dividends of 0.04 per share. The dividend payout ratio of -42.81 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -0.52, meaning Chengdu Olymvax Biopharmaceuticals Inc. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Chengdu Olymvax Biopharmaceuticals Inc. Class A has an Altman Z-Score of 9.44, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.